Silica Corpora
Silica Corpora is a biotechnology company leveraging a proprietary AI-powered platform for the de novo design and optimization of therapeutic antibodies. Their platform works exclusively with amino acid sequences, enabling the generation of antibody candidates with high efficiency, precision, and control. Key modules include the 'Generator' for creating antibody candidates, the 'Discriminator' for predicting properties like developability and stability, the 'Optimizer' for adapting candidates to specific target product profiles, and 'Ep-Mapper' for predicting epitopes. The company aims to revolutionize drug discovery by reducing the time and cost associated with bringing new drugs to market, offering a more accurate and cost-effective approach. They position themselves as a therapeutic development partner, capable of integrating with clients' existing data to accelerate programs and improve drug candidate quality. Silica Corpora was founded in 2022 and focuses on diseases with high unmet needs, guided by values of reducing animal testing, sustainability, democratizing drug discovery, and removing cost barriers.
Silica Corpora
Silica Corpora is a biotechnology company leveraging a proprietary AI-powered platform for the de novo design and optimization of therapeutic antibodies. Their platform works exclusively with amino acid sequences, enabling the generation of antibody candidates with high efficiency, precision, and control. Key modules include the 'Generator' for creating antibody candidates, the 'Discriminator' for predicting properties like developability and stability, the 'Optimizer' for adapting candidates to specific target product profiles, and 'Ep-Mapper' for predicting epitopes. The company aims to revolutionize drug discovery by reducing the time and cost associated with bringing new drugs to market, offering a more accurate and cost-effective approach. They position themselves as a therapeutic development partner, capable of integrating with clients' existing data to accelerate programs and improve drug candidate quality. Silica Corpora was founded in 2022 and focuses on diseases with high unmet needs, guided by values of reducing animal testing, sustainability, democratizing drug discovery, and removing cost barriers.